The American Diabetes Association (ADA) issued Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024 [21], which pointed out that initiation of insulin should be considered regardless of background glucose lowering therapy or disease stage if symptoms of hyperglycemia are present, or when A1C is very high (> 10%). Here, INS is linked to Hyperglycemia.